Navigation Links
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Date:5/19/2009

forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 "Understanding Mental Disorders: Your ... 1 by American Psychiatric Publishing, a division of the ... 1pm at the National Press Club in Washington, D.C.. ... moderated by APA President Paul Summergrad, MD. Guest speakers ... the foreword to the book; Paul Gionfriddo, President and ...
(Date:4/27/2015)... On April 16, 2015, Harper’s Bazaar Magazine, in an ... ,” interviewed a UK dermatologist on the causes and treatment ... a type of scar that reportedly affects nearly 90% of ... the elsastin and collagen in the dermis, the dense layer ... removal with the Coolbeam protocol is one of our most ...
(Date:4/27/2015)... Beckman Coulter is sponsoring a ... the evolution of neural circuitry and swimming behavior of ... mechanisms by which analogous forms of swimming behavior, such ... independently in certain sea slug clades. The webinar is ... 30, 2015 at 8:00am PT. , Sea slugs (Mollusca, ...
(Date:4/27/2015)... Sitting or standing for long periods of ... and for those whose occupation requires them to be sitting ... drivers, or to be on their feet for most of ... be more severe and longer lasting. These people suffer from ... Revana of Northeast Houston Vein Center is offering tips on ...
(Date:4/27/2015)... 27, 2015 FMC Corporation’s Health and ... wide range of market leading ingredients and solutions at ... Geneva, Switzerland. Vitafoods Europe 2015 expects to host 14,000 ... the latest research in such areas as digestive health, ... FMC Health and Nutrition’s booth will feature its world ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... US Food and Drug Administration has approved a new ... uses radiofrequency energy to// shrink small areas of the ... eyeball. Unlike laser in situ keratomileusis (LASIK), in which ... laser, conductive keratoplasty does not require cutting or tissue ...
... high serum concentrations of estrogen and testosterone have about ... with relatively low serum concentrations of these sex hormones. ... developing breast cancer were not different in women who ... hormone levels in these women were not a preclinical ...
... have to drink more to feel drunk than non-smoking drinkers ... brains, livers and hearts, a new study suggests.// ,The ... which are considered a good model for humans.Since alcohol abusers ... alcohol to get an expected level of intoxication, say the ...
... has found that young women are much more likely to ... contradicts the stereotype that men// are more likely to die ... Medicine this week. ,Researchers from Emory, Yale and Massachusetts ... discharged from hospital after a heart attack. They found that ...
... forget whole grains, if you want to cut your risk for ... and vegetables especially cruciferous vegetables like broccoli, cauliflower and cabbage ... According to a study of a group of 65,000 women, those ... bread each day were 30% to 40% less likely to have ...
... may help to protect the liver from damage, ... and 22 other fruits to laboratory rats. //The rats ... damage by interfering with cell synthesis and results in ... least amount of liver damage. ,The Researchers discovered ...
Cached Medicine News:
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., ... for curative treatment of chronic hepatitis B virus (HBV) ... for its lead HBV core inhibitor candidate, NVR 3-778, ... for the Study of the Liver (EASL) in ... activity of NVR 3-778 from studies performed in a ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
(Date:4/27/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... before the open of the U.S. financial markets on May ... host a conference call and webcast at 9:00 a.m. ET ... the call is U.S./ Canada (866) 497-0462, ... dial in 10 minutes prior to the scheduled start time. ...
Breaking Medicine Technology:Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
... organizations, community leaders, health care professionals, and people of ... today urged Express Scripts to get back to the ... access to pharmacy services for hundreds of millions of ... put the people of our communities at the forefront ...
Cached Medicine Technology:Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2Over 130 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2
IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
... RSV Test utilizes a new, improved format that ... rapid RSV detection. The testing device employs innovative ... reagents have already been applied to the testing ... with clear-cut results shown by the appearance of ...
Latex agglutination slide test for the qualitative detection of rotavirus from fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: